Alnylam Pharmaceuticals
ALNY
#638
Rank
S$42.72 B
Marketcap
$329.31
Share price
-0.59%
Change (1 day)
32.57%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.55. In 2022 the company made an earnings per share (EPS) of -$12.54 a decrease over its 2021 EPS that were of -$9.72.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-56.16%
2022-$12.5429.03%
2021-$9.72-3.36%
2020-$10.06-8.48%
2019-$10.997.67%
2018-$10.2039.74%
2017-$7.3012.94%
2016-$6.4738.84%
2015-$4.66-32.88%
2014-$6.94259.44%
2013-$1.93-31.25%
2012-$2.8152.94%
2011-$1.8430.77%
2010-$1.40-8.77%
2009-$1.5478.13%
2008-$0.86-70.78%
2007-$2.9699.09%
2006-$1.48-43.88%
2005-$2.65-82.33%
2004-$14.97-59.23%
2003-$36.73

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.29-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$50.42-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$10.57 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.36-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.28-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.05-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.29-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.70-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel